
Please try another search
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It offers AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was founded in 2020 and is based in Dana Point, California.
Name | Age | Since | Title |
---|---|---|---|
Patricia Reggio | - | - | Member of Scientific Advisory Board |
Rangan Maitra | - | - | Member of Scientific Advisory Board |
Salman Hoda | 44 | 2020 | Director |
Martin Schroeder | - | - | Chief Scientific Officer & Member of Scientific Advisory Board |
Riazul Huda | 56 | 2020 | CEO, CFO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review